Dyne Therapeutics Announces CEO Transition
25 Março 2024 - 8:30AM
Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle
disease company focused on advancing innovative life-transforming
therapeutics for people living with genetically driven diseases,
today announced the appointment of John Cox as president, chief
executive officer (CEO) and a member of the Board of Directors,
effective immediately. He succeeds Joshua Brumm, who has chosen to
step down from these roles to pursue a career in healthcare
investing. Mr. Brumm will serve as an advisor to Dyne to help
ensure a seamless transition.
“I’m thrilled to join Dyne. I was drawn to the recent compelling
clinical data for the DM1 and DMD programs and the potential to
leverage the FORCE™ platform in other diseases. Having worked
extensively in rare diseases, I appreciate the meaningful impact
that novel therapeutics can have on a patient community,” said Mr.
Cox. “I’m looking forward to working with the team to further
advance our clinical programs and our pipeline and to build
additional capabilities as Dyne continues to create value for all
its stakeholders.”
“It’s been a great privilege to lead Dyne since 2019. I want to
thank the Board and all Dynamos for their support, and I’m proud of
all that we have accomplished together,” said Mr. Brumm. “This is
the right time to hand the reins to John to work with the
incredible Dyne team to prepare for the company’s exciting next
phase and continued pursuit of its mission of delivering
life-transforming therapies for patients.”
“I want to thank Josh for his leadership as Dyne transitioned
from a research organization to a clinical-stage company. It’s
remarkable what he and the team have achieved in such a short
period of time, and the company is well positioned for future
success,” said Jason Rhodes, chairman of Dyne’s Board of Directors.
“We are delighted to have John joining Dyne and fortunate to have
someone with such deep executive experience, including in rare
disease commercialization and global operations, leading the
company’s next chapter.”
Mr. Cox brings to Dyne extensive executive experience in the
biotechnology industry across various operating roles, including
rare disease commercialization. Mr. Cox was CEO of Bioverativ Inc.,
a rare disease spin-off from Biogen Inc., from 2017-2018, during
which time the company grew to $1.1 billion in global sales and
nearly 500 employees before being acquired by Sanofi S.A. Most
recently, he served as CEO of Repertoire Immune Medicines and its
predecessor from 2019 until 2022. Mr. Cox held various roles of
increasing responsibility during a 14-year tenure at Biogen,
including as executive vice president, global commercial &
technical operations. Mr. Cox holds an MBA from the University of
Michigan, an M.S. in cell biology from California State University
and a B.S. in biology from Arizona State University.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company
focused on advancing innovative life-transforming therapeutics for
people living with genetically driven diseases. With its
proprietary FORCE™ platform, Dyne is developing modern
oligonucleotide therapeutics that are designed to overcome
limitations in delivery to muscle tissue. Dyne has a broad pipeline
for serious muscle diseases, including clinical programs for
myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy
(DMD) and a preclinical program for facioscapulohumeral muscular
dystrophy (FSHD). For more information, please visit
https://www.dyne-tx.com/, and follow us on X, LinkedIn and
Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, contained in this press
release, including statements regarding Dyne’s strategy, future
operations, prospects and plans, objectives of management and the
potential of the FORCE platform, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. The words “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,”
“objective,” “ongoing,” “plan,” “predict,” “project,” “potential,”
“should,” or “would,” or the negative of these terms, or other
comparable terminology are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Dyne may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements as a result of various important
factors, including: uncertainties inherent in the identification
and development of product candidates, including the initiation and
completion of preclinical studies and clinical trials;
uncertainties as to the availability and timing of results from
preclinical studies and clinical trials; the timing of and Dyne’s
ability to initiate and enroll patients in clinical trials; whether
results from preclinical studies and initial data from early
clinical trials will be predictive of the final results of the
clinical trials or future trials; whether Dyne’s cash resources
will be sufficient to fund the Company’s foreseeable and
unforeseeable operating expenses and capital expenditure
requirements; as well as the risks and uncertainties identified in
Dyne’s filings with the Securities and Exchange Commission (SEC),
including the Company’s most recent Annual Report on Form 10-K and
in subsequent filings Dyne may make with the SEC. In addition, the
forward-looking statements included in this press release represent
Dyne’s views as of the date of this press release. Dyne anticipates
that subsequent events and developments will cause its views to
change. However, while Dyne may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Dyne’s views as of any date subsequent to the date of
this press release.
Contacts:
InvestorsAmy Reillyareilly@dyne-tx.com
857-341-1203
MediaStacy
Nartkersnartker@dyne-tx.com781-317-1938
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/0d3a30c3-9597-403a-aee3-fb737a178c13
Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Dyne Therapeutics (NASDAQ:DYN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024